+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastric Cancer Drugs Market Research Report by Route of Administration (Oral and Parenteral), by Molecule Type (Biologics and Small Molecules), by Lines of Chemotherapy, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5122731
  • Report
  • September 2021
  • Region: United States
  • 63 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The United States Gastric Cancer Drugs Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Gastric Cancer Drugs Market.

Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Gastric Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Route of Administration, the Gastric Cancer Drugs Market was studied across Oral and Parenteral.
  • Based on Molecule Type, the Gastric Cancer Drugs Market was studied across Biologics and Small Molecules.
  • Based on Lines of Chemotherapy, the Gastric Cancer Drugs Market was studied across First-line Chemotherapy and Second-line Chemotherapy.
  • Based on State, the Gastric Cancer Drugs Market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Gastric Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Gastric Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Gastric Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Gastric Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the United States Gastric Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the United States Gastric Cancer Drugs Market?
6. What is the market share of the leading vendors in the United States Gastric Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the United States Gastric Cancer Drugs Market?
Note: Product cover images may vary from those shown
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Route of Administration Outlook
3.4. Molecule Type Outlook
3.5. Lines of Chemotherapy Outlook
3.6. State Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges

6. Gastric Cancer Drugs Market, by Route of Administration
6.1. Introduction
6.2. Oral
6.3. Parenteral

7. Gastric Cancer Drugs Market, by Molecule Type
7.1. Introduction
7.2. Biologics
7.3. Small Molecules

8. Gastric Cancer Drugs Market, by Lines of Chemotherapy
8.1. Introduction
8.2. First-line Chemotherapy
8.3. Second-line Chemotherapy

9. California Gastric Cancer Drugs Market
9.1. Introduction

10. Florida Gastric Cancer Drugs Market
10.1. Introduction

11. Illinois Gastric Cancer Drugs Market
11.1. Introduction

12. New York Gastric Cancer Drugs Market
12.1. Introduction

13. Ohio Gastric Cancer Drugs Market
13.1. Introduction

14. Pennsylvania Gastric Cancer Drugs Market
14.1. Introduction

15. Texas Gastric Cancer Drugs Market
15.1. Introduction

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 (USD MILLION)
FIGURE 3. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2020 (USD MILLION)
FIGURE 4. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2020 (USD MILLION)
FIGURE 5. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 6. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 7. UNITED STATES GASTRIC CANCER DRUGS MARKET: MARKET DYNAMICS
FIGURE 8. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (%)
FIGURE 9. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2026
FIGURE 11. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
FIGURE 12. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 13. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2026 (USD MILLION)
FIGURE 14. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 15. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2020 VS 2026 (%)
FIGURE 16. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2026
FIGURE 18. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2026 (USD MILLION)
FIGURE 19. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 20. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2026 (USD MILLION)
FIGURE 21. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 22. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2020 VS 2026 (%)
FIGURE 23. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2020 VS 2026 (USD MILLION)
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2026
FIGURE 25. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, 2018-2026 (USD MILLION)
FIGURE 26. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 27. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, 2018-2026 (USD MILLION)
FIGURE 28. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 29. CALIFORNIA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 30. FLORIDA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 31. ILLINOIS GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 32. NEW YORK GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 33. OHIO GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 34. PENNSYLVANIA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 35. TEXAS GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 36. UNITED STATES GASTRIC CANCER DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 37. UNITED STATES GASTRIC CANCER DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 38. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES GASTRIC CANCER DRUGS MARKET, BY TYPE

List of Tables
TABLE 1. UNITED STATES GASTRIC CANCER DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD MILLION)
TABLE 5. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY STATE, 2018-2026 (USD MILLION)
TABLE 6. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY STATE, 2018-2026 (USD MILLION)
TABLE 7. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2026 (USD MILLION)
TABLE 8. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY STATE, 2018-2026 (USD MILLION)
TABLE 9. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY STATE, 2018-2026 (USD MILLION)
TABLE 10. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2026 (USD MILLION)
TABLE 11. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, BY STATE, 2018-2026 (USD MILLION)
TABLE 12. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, BY STATE, 2018-2026 (USD MILLION)
TABLE 13. CALIFORNIA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 14. FLORIDA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 15. ILLINOIS GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 16. NEW YORK GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 17. OHIO GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 18. PENNSYLVANIA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 19. TEXAS GASTRIC CANCER DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 20. UNITED STATES GASTRIC CANCER DRUGS MARKET: SCORES
TABLE 21. UNITED STATES GASTRIC CANCER DRUGS MARKET: BUSINESS STRATEGY
TABLE 22. UNITED STATES GASTRIC CANCER DRUGS MARKET: PRODUCT SATISFACTION
TABLE 23. UNITED STATES GASTRIC CANCER DRUGS MARKET: RANKING
TABLE 24. UNITED STATES GASTRIC CANCER DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 25. UNITED STATES GASTRIC CANCER DRUGS MARKET: MERGER & ACQUISITION
TABLE 26. UNITED STATES GASTRIC CANCER DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 27. UNITED STATES GASTRIC CANCER DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 28. UNITED STATES GASTRIC CANCER DRUGS MARKET: INVESTMENT & FUNDING
TABLE 29. UNITED STATES GASTRIC CANCER DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 30. UNITED STATES GASTRIC CANCER DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll